QIAGEN today announced plans to combine its three Maryland sites into two campuses and invest an additional $10 million to accommodate expected future growth. The company will close its current site at Gaithersburg, Maryland and move the Gaithersburg activities to nearby Germantown, Maryland, by early 2015. The Germantown campus will also become the manufacturing site for some of QIAGEN's highest-volume diagnostic assays, including the digene HC2 HPV Test for cervical cancer prevention, after passing a recent FDA pre-approval inspection with no "483" observations (or non-conformances). In the future QIAGEN also plans to move manufacturing to Germantown for the rapidly growing QuantiFERON-TB Gold test for latent tuberculosis (TB).
QIAGEN's campus in Frederick, Maryland, less than 20 miles from the Germantown site, already has expanded in the past three years and will continue its focus on R&D and manufacturing of molecular testing products for life sciences research and other applications.
"Combining three Maryland sites into two will strengthen our presence by bringing QIAGEN's people together to encourage closer collaboration. At Germantown, we are creating a global focus on Molecular Diagnostics for disease prevention, including women's health and tuberculosis, by placing our R&D teams on the same campus with marketing and manufacturing for those products," said Douglas Liu, Senior Vice President, Operations. "QIAGEN's investment of $10 million in the Maryland locations, added to our investment over the past two years, brings our total recent commitment to $50 million. This upgrade will prepare us for expected growth in the coming years, including moving additional support to Maryland for several rapidly growing product lines." Sean Augerson, Vice President Supply Chain & Strategic Partner Management, added: "We are very pleased with the successful FDA pre-approval inspection for the Germantown site to manufacture our digene HC2 HPV Test, the world's gold standard molecular diagnostic for prevention of cervical cancer in women. Uniting multiple functions at the Germantown campus will help QIAGEN continue to serve diagnostic laboratories with the highest-quality, reliable technologies to make improvements in life possible." QIAGEN currently has a total of approximately 550 employees at the three Maryland sites. The Gaithersburg facility was leased, while the Germantown facility is owned by QIAGEN.